Search Results - "Sánchez‐Torres, José Miguel"

Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic by Toquero, Patricia, Blanco Fernández, Carmen, López Martí, María Pilar, Hernández Marín, Berta, Vera Cea, E Beatriz, Garrido García, Ana, Méndez Carrascosa, Elena, Bañón Torres, Dulce, Donnay Candil, Olga, Ballesteros García, Ana Isabel, Sánchez-Torres, José Miguel, Costas Rojo, Pablo, Mondéjar, Rebeca, Colomer, Ramon, Romero-Laorden, Nuria

“…The COVID-19 pandemic has caused mental health problems worldwide. The psychopathological implications of COVID-19 in cancer patients have rarely been…”
Get full text

Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC by Rogado, Jacobo, Pozo, Fernando, Troule, Kevin, Sánchez-Torres, José Miguel, Romero-Laorden, Nuria, Mondejar, Rebeca, Donnay, Olga, Ballesteros, Anabel, Pacheco-Barcia, Vilma, Aspa, Javier, Al-Shahrour, Fátima, Alfranca, Arantzazu, Colomer, Ramon

“…In lung cancer immunotherapy, biomarkers to guide clinical decisions are limited. We now explore whether the detailed immunophenotyping of circulating…”
Get full text

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain by Arriola, Edurne, García Gómez, Ramón, Diz, Pilar, Majem, Margarita, Martínez Aguillo, Maite, Valdivia, Javier, Paredes, Alfredo, Sánchez-Torres, José Miguel, Peralta Muñoz, Sergio, Barneto, Isidoro, Gutierrez, Vanesa, Andrade Santiago, Jesús Manuel, Aparisi, Francisco, Isla, Dolores, Ponce, Santiago, Vicente Baz, David, Artal, Angel, Amador, Mariluz, Provencio, Mariano

“…Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several…”
Get full text

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer by Aparicio, Inmaculada, Iranzo, Patricia, Reyes, Roxana, Bote, Helena, Saigi, María, Bringas, Marianela, Bosch-Barrera, Joaquim, Corral, Jesús, Aparisi, Francisco, Ruffinelli, Jose C., Jiménez, Beatriz, Lage, Yolanda, López-Castro, Rafael, Majem, Margarita, Vázquez, Sergio, Artal, Ángel, Rodríguez-Pérez, Ángel, Lázaro-Quintela, Martín, Torres, José Miguel Sánchez, Reguart, Noemí, Cucurull, Marc, Gil-Bazo, Ignacio, Camps, Carlos, Nadal, Ernest, del Barrio, Anabel, Garrido, Pilar, Dómine, Manuel, Álvarez, Rosa, Muñoz, Andrés J., Calles, Antonio

“…INTRODUCTIONWe aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected.METHODSBetween 2008 and 2021,…”
Get full text

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program by Bernabé-Caro, Reyes, Garrido, Pilar, García-Campelo, Rosario, Palmero, Ramón, Artal, Ángel, Bayona, Cristina, Rodríguez-Abreu, Delvys, López-Brea, Marta, Paredes, Alfredo, Vicente, David, Sánchez Torres, José Miguel, Majem, Margarita, Diz, Pilar, Gordo, Rocío, Coca, Margarita, de Castro, Javier

“…This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive…”
Get full text

Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study by Moran, Teresa, Taus, Alvaro, Arriola, Edurne, Aguado, Carlos, Dómine, Manuel, Rueda, Ana Gómez, Calles, Antonio, Cedrés, Susana, Viñolas, Nuria, Isla, Dolores, Palmero, Ramón, Sereno, María, Diaz, Victor, Juan, Oscar, Marsé, Raquel, Martorell, Paloma Martín, Sánchez Torres, José Miguel, Anguera, Georgia, Bosch, Joaquim, Cabezón, Luis, Catot, Silvia, Martinez, Alex, Muñoz, Silvia, Ramos, Inmaculada

“…Uncommon epidermal growth factor receptor (EGFR) mutations (u-EGFRm) are a heterogeneous group of molecular alterations and have also been reported as…”
Get full text

A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy by Sánchez-Alonso, Santiago, Setti-Jerez, Giulia, Arroyo, Montserrat, Hernández, Tathiana, Martos, Mª Inmaculada, Sánchez-Torres, Jose Miguel, Colomer, Ramon, Ramiro, Almudena R, Alfranca, Arantzazu

“…BackgroundLung cancer is one of the most frequent malignancies in humans and is a major cause of death. A number of therapies aimed at reinforcing antitumor…”
Get full text

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies by Rogado, Jacobo, Romero-Laorden, Nuria, Sanchez-Torres, José Miguel, Ramos-Levi, Ana María, Pacheco-Barcia, Vilma, Ballesteros, Ana Isabel, Arranz, Reyes, Lorenzo, Alicia, Gullon, Pedro, Garrido, Ana, Serra López-Matencio, José María, Donnay, Olga, Adrados, Magdalena, Costas, Pablo, Aspa, Javier, Alfranca, Arantzazu, Mondejar, Rebeca, Colomer, Ramon

“…Immunotherapy is an effective treatment in advanced cancer, although predictors of response are limited. We studied whether excess weight influences the…”
Get full text

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors by Sánchez-Torres, José Miguel, Viteri, Santiago, Molina, Miguel Angel, Rosell, Rafael

“…Inhibitors targeting active protein kinases, such as EGFR or ALK, have demonstrated significant efficacy in the treatment of lung cancer. Activating mutations…”
Get full text

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology by Garrido, Pilar, Paz‐Ares, Luis, Majem, Margarita, Morán, Teresa, Trigo, José Manuel, Bosch‐Barrera, Joaquim, Garcίa‐Campelo, Rosario, González‐Larriba, José Luis, Sánchez‐Torres, José Miguel, Isla, Dolores, Viñolas, Núria, Camps, Carlos, Insa, Amelia, Juan, Óscar, Massuti, Bartomeu, Paredes, Alfredo, Artal, Ángel, López‐Brea, Marta, Palacios, José, Felip, Enriqueta

“…Objectives The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology…”
Get full text

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies by Lin, Luping, Sabnis, Amit J, Chan, Elton, Olivas, Victor, Cade, Lindsay, Pazarentzos, Evangelos, Asthana, Saurabh, Neel, Dana, Yan, Jenny Jiacheng, Lu, Xinyuan, Pham, Luu, Wang, Mingxue M, Karachaliou, Niki, Cao, Maria Gonzalez, Manzano, Jose Luis, Ramirez, Jose Luis, Torres, Jose Miguel Sanchez, Buttitta, Fiamma, Rudin, Charles M, Collisson, Eric A, Algazi, Alain, Robinson, Eric, Osman, Iman, Muñoz-Couselo, Eva, Cortes, Javier, Frederick, Dennie T, Cooper, Zachary A, McMahon, Martin, Marchetti, Antonio, Rosell, Rafael, Flaherty, Keith T, Wargo, Jennifer A, Bivona, Trever G

“…Trever Bivona and colleagues show that the Hippo pathway effector YAP promotes resistance to RAF and MEK inhibitor therapy in multiple types of BRAF -mutant…”
Get full text

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance by Zugazagoitia, Jon, Gómez-Rueda, Ana, Jantus-Lewintre, Eloisa, Isla, Dolores, Camps, Carlos, Ramos, Inmaculada, Trigo, Jose Manuel, Bernabé, Reyes, Juan-Vidal, Oscar, Sanchez-Torres, Jose Miguel, García-Campelo, Rosario, Provencio, Mariano, Felip, Enriqueta, de Castro, Javier, Faull, Iris, Lanman, Richard B., Ponce-Aix, Santiago, Paz-Ares, Luis, Garrido, Pilar

“…•Multicenter prospective study including 53 EGFR/ALK/ROS1-TKI-resistant patients.•Thirty-four patients (64%) had evidence of tumor-DNA shed for resistance…”
Get full text

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial by Provencio, Mariano, Ortega, Ana Laura, Coves-Sarto, Juan, Calvo, Virginia, Marsé-Fabregat, Raquel, Dómine, Manuel, Guirado, María, Carcereny, Enric, Fernández, Natalia, Álvarez, Ruth, Blanco, Remei, León-Mateos, Luis, Sánchez-Torres, José Miguel, Sullivan, Ivana Gabriela, Cobo, Manuel, Sánchez-Hernández, Alfredo, Massuti, Bartomeu, Sierra-Rodero, Belen, Mártinez-Toledo, Cristina, Serna-Blasco, Roberto, Romero, Atocha, Cruz-Bermúdez, Alberto

“…Antiangiogenic drug combinations with anti-programmed cell death 1 protein and anti-programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment…”
Get more information

Excess weight and anti-PD-1 immune checkpoint inhibitor’s outcomes in non-small cell lung cancer by Rogado, Jacobo, Pozo, Fernando, Troulé, Kevin, Sánchez-Torres, José Miguel, Romero-Laorden, Nuria, Mondejar, Rebeca, Donnay, Olga, Ballesteros, Anabel, Pacheco-Barcia, Vilma, Aspa, Javier, Al-Shahrour, Fátima, Alfranca, Arantzazu, Colomer, Ramon

“…Purpose Immune checkpoint inhibitors are one of the most effective treatments available in advanced non-small cell lung cancer. However, at present, there are…”
Get full text

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy by Gómez Rueda, Ana, Taus, Álvaro, Álvarez Álvarez, Rosa, Bernabé-Caro, Reyes, Chara, Luis, López-Brea, Marta, Vilà, Laia, Sala González, Maria Ángeles, del Barrio Díaz Aldagalán, Anabel, Esteban Herrera, Beatriz, López Castro, Rafael, Álvarez Cabellos, Ruth, Doménech, Marta, Falagan, Sandra, Moreno Vega, Alberto, Aguado, Carlos, Barba, Andrés, Delgado Ureña, Maria Teresa, Isla, Dolores, Bellido Hernández, Lorena, Fírvida Pérez, José Luis, Juan-Vidal, Óscar, Massutí, Bartomeu, Mielgo-Rubio, Xabier, Ortega, Ana Laura, Catot, Silvia, Dómine, Manuel, Escoín-Pérez, Corina, García Navalón, Francisco, Gil-Bazo, Ignacio, Muñoz, Silvia, Rodríguez-Abreu, Delvys, Villatoro Roldán, Rosa María, Alonso-Jáudenes Curbera, Guillermo, León-Mateos, Luis, Padilla, Airam, Paredes Lario, Alfredo, Sánchez-Torres, José Miguel, Garrido, Pilar

“…Objectives The S-REAL study aimed to assess the effectiveness of durvalumab as consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world…”
Get full text

Nivolumab-induced thyroid dysfunction in patients with lung cancer by Ramos-Levi, Ana M, Rogado, Jacobo, Sanchez-Torres, Jose Miguel, Colomer, Ramón, Marazuela, Mónica

“…Nivolumab is an anti-cancer monoclonal antibody that inhibits PD1 and modulates T-cell response. It has been shown to significantly improve survival in several…”
Get more information

PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study by Rubio-Viqueira, Belen, Tarruella, Margarita Majem, Lázaro, Martín, Estévez, Sergio Vázquez, Córdoba-Ortega, Juan Felipe, Maiques, Inmaculada Maestu, González, Jorge García, Cordellat, Ana Blasco, Valdivia-Bautista, Javier, Arenas, Carmen González, Sánchez Torres, Jose Miguel

“…To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in…”
Get full text

Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid by DICKGREBER, Nicolas J, BENN SORENSEN, Jens, PAZ-ARES, Luis G, KJESTRUP SCHYTTE, Tine, LATZ, Jane E, SCHNECK, Karen B, ZHENG YUAN, SANCHEZ-TORRES, José Miguel

“…Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC)…”
Get full text

Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients by Serna, Roberto, Sanchez, Alfredo, De Julian, Maria, García Girón, Carlos, Domine, Manuel, Blasco, Ana, Sanchez Torres, Jose Miguel, Oramas, Juana, Bosch-Barrera, Joaquim, Sala, Maria Angeles, Sereno, Maria, Ortega, Ana Laura, Chara Velarde, Luis Enrique, Hernandez, Berta, Padilla, Airam, Coves, Juan, Jantus Lewintre, Eloisa, Molina-Vila, Miguel Angel, Romero, Atocha, Provencio-Pulla, Mariano

“…Abstract only e21196 Background: Non-small cells lung cancer (NSCLC) patients treated with Tyrosine Kinase Inhibitors (TKI) at first-line ultimately develop…”
Get full text

Clinical and molecular characteristics of the patients in the liquid biopsy study in mEGFR-NSCLC in a Spanish population (OPH-1) by Franco, Fernando, Serna, Roberto, Sanchez, Alfredo, García Girón, Carlos, Domine, Manuel, Camps, Carlos, Sanchez Torres, Jose Miguel, Oramas Rodriguez, Juana Maria, Chara Velarde, Luis Enrique, Ortega, Ana Laura, Sala, Maria Angeles, Hernandez, Berta, Sereno, Maria, Bosch-Barrera, Joaquim, Padilla, Airam, Balsalobre Yago, Jose, Blanco, Remei, Mielgo, Xabier, Romero, Atocha, Provencio-Pulla, Mariano

“…Abstract only e21515 Background: The liquid biopsy (LB) is an important tool in the diagnostic and follow up of the patients with non-small cell lung cancer…”
Get full text